Recently, PD-1/PD-L1 blockade has emerged as a therapeutic strategy for patients with cancer [2], and has been approved for the first-line and second-line treatment of patients with non-small-cell lung cancer (NSCLC) [3]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.